翻訳と辞書 |
fesoterodine : ウィキペディア英語版 | fesoterodine
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).〔(【引用サイトリンク】 title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights )〕 It was approved by the European Medicines Agency in April 2007,〔(【引用サイトリンク】 title=Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08 )〕 the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.〔(Notice of Decision for TOVIAZ )〕 Fesoterodine is a prodrug. It is broken down into its active metabolite, ''5-hydroxymethyl tolterodine'', by plasma esterases. ==Efficacy== Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「fesoterodine」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|